PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ioflupane→

Ioflupane PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
155797-99-2
Molecular formula
C18H23FINO2
Molecular weight
431.3 g/mol
Drug class
Iodine-123 labelled dopamine transporter (DAT) radioliganddiagnostic radiopharmaceutical
Mechanism of action
Ioflupane binds to dopamine transporters on presynaptic dopaminergic nerve terminals in the striatum. After labelling with iodine-123, its regional distribution is visualised using SPECT; reduced striatal uptake indicates loss of functional dopaminergic terminals.
Indications / reported uses
  • Diagnostic SPECT imaging in adults with clinically uncertain parkinsonian syndromes to help differentiate essential tremor from presynaptic parkinsonian syndromes
  • Adjunctive imaging to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease; the scan does not distinguish Parkinson’s disease from multiple system atrophy or progressive supranuclear palsy

Sources: EMA EPAR — DaTSCAN · UK SmPC — DaTSCAN (updated 13 Jul 2026) · US DailyMed — DaTSCAN (updated 24 Apr 2026) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Ioflupane PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ioflupane Permitted Daily Exposure (PDE) report (the Ioflupane PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ioflupane Occupational Exposure Limit (OEL) report (the Ioflupane OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.